Acquiring Company
Samsung Biologics
Acquired Company
PolyPeptide Group AG
South Korea
SwitzerlandManufacturingBiotechnologyManufacturingBiotechnologyDescription
Samsung Biologics has announced an all-cash tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share, totaling approximately CHF 1.46 billion. This acquisition aims to enhance Samsung Biologics' capabilities in peptide therapeutics amidst growing market demand. PolyPeptide's expertise in manufacturing and development will complement Samsung Biologics' existing operations, positioning both companies for expanded growth in the biopharmaceutical sector.
Other recent acquisitions in Manufacturing and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Senores Pharma acquires 75% stake in Apnar Pharma (August 30, 2026)
- Indo Borax to acquire 64.26% stake in Kronox Labs (August 29, 2026)
- Piramal Pharma acquires majority stake in Yapan Bio (August 18, 2026)
- Medios acquires 74% of Caelo to enhance growth (August 12, 2026)
- New Green Hemp acquires EcoGreen Biotech for growth (August 4, 2026)
- Sumitomo Chemical finalizes Koei share swap (August 4, 2026)
Who to call at Samsung Biologics, and when
When Samsung Biologics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Samsung Biologics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Samsung Biologics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Samsung Biologics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Samsung Biologics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired PolyPeptide Group AG?
PolyPeptide Group AG was acquired by Samsung Biologics, based in South Korea. The deal was reported on July 19, 2026. Samsung Biologics is a fully integrated contract development and manufacturing organization (CDMO) that offers comprehensive services from cell line development to final aseptic fill/finish. Samsung Biologics is privately held and operates in Manufacturing.
When did Samsung Biologics acquire PolyPeptide Group AG?
Samsung Biologics's acquisition of PolyPeptide Group AG was reported on July 19, 2026. Samsung Biologics has announced an all-cash tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share, totaling approximately CHF 1.46 billion. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does PolyPeptide Group AG do?
PolyPeptide Group AG is a prominent contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs). It is privately held, operating in Manufacturing, and is based in Switzerland.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.